Novo Nordisk's Two-Speed Reality: Legal Wins and Buybacks Mask a Pipeline Under Scrutiny
Published on 08/11/2026 at 08:12 | Redaktion boerse-global.de
The Danish pharmaceutical giant finds itself in an unusual position: defending its intellectual property in a Dutch courtroom while simultaneously defending its growth narrative to increasingly skeptical investors. A court in The Hague ruled on August 5 in favor of Novo Nordisk, issuing a preliminary injunction against Dutch pharmacy Ceban Ziekenhuisfarmacie B.V. over its compounded semaglutide nasal spray, which the court determined infringed on Novo Nordisk's intellectual property rights. The ruling forces an immediate halt to sales of the imitation product.
The legal victory, however, lands at a moment when the company's operational momentum is visibly cooling. Novo Nordisk reported second-quarter 2026 adjusted sales growth of 7 percent and adjusted operating profit growth of 11 percent, both at constant exchange rates. Yet the company's full-year guidance tells a more cautious story: management now expects adjusted sales growth between 0 and minus 6 percent at constant exchange rates, with the same range applied to adjusted operating profit.
That revised outlook represents a notable shift from earlier expectations. The company had previously guided for a decline of 4 to 12 percent in adjusted sales, meaning the latest figures actually reflect an improvement in management's thinking. The upgrade was driven by stronger expectations for the GLP-1 product portfolio compared with the May forecast. But the brighter headline masks a costly complication: the company booked non-cash impairment charges of 6.3 billion Danish kroner on intangible pipeline assets, with 4.0 billion kroner attributable to the drug candidate Monlunabant alone.
The Pill's Promising Start and the American Headwind
The newly launched tablet version of Wegovy generated 3.22 billion kroner in second-quarter sales, marginally missing the 3.27 billion kroner analysts had anticipated. Since its market debut in January 2026, the pill has nonetheless amassed more than 5 million prescriptions, evidence that underlying demand remains intact. The shortfall against expectations, however modest, adds to a pattern of incremental disappointments.
The United States presents a more structural challenge. Novo Nordisk itself anticipates declining sales in its most important market, citing current prescription trends for GLP-1 injections, intensifying competitive pressure, and the impact of reduced Medicaid reimbursement for obesity medications. That trifecta of headwinds is eating into margins even as the company's oral formulation gains traction.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
A Pipeline That Stutters Where It Matters Most
The ZEUS cardiovascular outcomes study, released in late July, delivered what the company itself acknowledged as a setback. Ziltivekimab demonstrated the expected biological effect by inhibiting the IL-6 signaling pathway, yet failed to measurably reduce the risk of major cardiovascular events compared with placebo — the hazard ratio came in at 0.99. Serious infections occurred more frequently among patients receiving the drug, and no difference in overall mortality was observed.
Novo Nordisk maintains that the ZEUS result does not alter its 2026 profit forecast, though it will trigger another non-cash impairment charge in the third quarter. Two additional studies of Ziltivekimab — HERMES, examining its use in heart failure, and ARTEMIS, looking at patients following heart attacks — remain ongoing, with results expected in the first half of 2027. The company also reported another underwhelming clinical outcome for its next-generation candidate CagriSema, further feeding doubts about the longer-term pipeline trajectory.
There are bright spots beyond the headlines. Long-term data from the FRONTIER4 study of Denecimig, a hemophilia A therapy, showed a favorable safety profile, and a US approval application has already been submitted. Shareholders, meanwhile, have received an interim dividend of 3.75 kroner per share alongside the ongoing buyback program, which had returned nearly 7.78 billion kroner to investors by early August. Total shareholder distributions for the first half reached 41.2 billion kroner.
Buybacks, Diverging Analyst Views, and a Stabilizing Share Price
The buyback program continues unabated despite the softened growth outlook. Through August 7, Novo Nordisk had repurchased 27,884,179 B-shares at an average price of 279.01 Danish kroner since February 4, representing a transaction volume of approximately 7.78 billion kroner. The sustained repurchase activity signals management's conviction that the current valuation remains attractive, even as the growth trajectory narrows.
Wall Street's assessment is divided. Citi lowered its price target on August 7 from 330 to 310 Danish kroner, while BMO Capital struck a more cautiously optimistic tone, raising its target from $45 to $47 on August 6. The opposing moves capture the central tension: robust second-quarter revenue growth on one side, a dimmed full-year outlook and a tepid pill launch on the other.
The share price has found some footing in recent sessions. The stock closed Monday at 41.20 euros, up 0.50 percent on the day, with a 7.18 percent gain over seven trading days. Yet it remains down 6.42 percent year-to-date, and the gap to its 52-week high of 54.86 euros — roughly 25 percent — underscores how far sentiment has traveled from the peak of the GLP-1 frenzy. The market appears willing to credit the operational recovery, but the pipeline has yet to earn back its premium.
Ad
Novo Nordisk Stock: New Analysis - 11 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
